EDIT
NasdaqEditas Medicine, Inc.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
🔒 price chart needs market-data feed$25.5M
2021
$19.7M
2022
$78.1M
2023
$32.3M
2024
$40.5M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$40.5M
Net Income$-160.1M
Gross Profit—
Oper Income$-160.0M
EPS (dil)$-1.80
Rev/sh$0.41
FCF/sh$-1.69
Book/sh$0.28
Gross M—
Oper M-394.9%
Profit M-395.0%
FCF M-409.3%
ROE-586.6%
ROA-85.8%
ROIC—
R&D/Rev222.0%
Rev Y/Y25.4%
Rev 3Y CAGR27.1%
EPS Y/Y37.5%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+7.8%
Current Ratio3.54
Quick Ratio—
Debt/Eq2.15
Int Coverage-75.2×
Net Debt$90.7M cash
Total Debt$58.6M
Cash & Eq$149.3M
Total Assets$186.5M
Oper CF$-165.2M
Capex$607,000
Free CF$-165.8M
Buybacks—
Equity$27.3M
Liabilities$159.2M
Shs Outstand0.10B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $25.5M | $19.7M | $78.1M | $32.3M | $40.5M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-193.1M | $-225.9M | $-169.2M | $-251.2M | $-160.0M |
| Net Income | $-192.5M | $-220.4M | $-153.2M | $-237.1M | $-160.1M |
| Diluted EPS | $-2.85 | $-3.21 | $-2.02 | $-2.88 | $-1.80 |
| Operating Cash Flow | $-163.8M | $-177.3M | $-132.2M | $-210.3M | $-165.2M |
| Free Cash Flow | $-171.8M | $-181.5M | $-136.9M | $-219.1M | $-165.8M |
COMMUNITY · $EDIT0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.